Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario – February 4, 2026 Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer. To date, 90 patients have been enrolled and treated with the Theralase® Study Procedure, achieving the patient enrollment specified by the statistical analysis plan. 78 patients have completed the clinical study and were evaluated at all scheduled assessment visits or were prematurely removed by the principal investigator due to lack of response. There are 12 patients pending study completion. Primary Endpoint Performance (CR at any Point in Time) # % Confidence Interval … Read More

TMX Newsfile | Feb 2, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 2, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully completed its targeted milestone of enrolling and treating 90 patients in a multi-center Phase II clinical study for bladder cancer. The Phase II clinical study has a primary endpoint of efficacy, a secondary endpoint of duration of response and a tertiary endpoint of safety, in evaluating light-activated Ruvidar® in the treatment of patients diagnosed with Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“), who have failed standard-of-care therapy and are facing radical cystectomy (bladder removal) (“Study II“). The … Read More

Toronto, Ontario, January 12, 2026 – Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have entered into a collaborative clinical development agreement (“Agreement”), on January 9, 2026. The Agreement builds on Theralase®’s existing clinical program (NCT03945162) with a new cohort investigating Theralase®’s investigational light-activated small molecule Ruvidar® (TLD-1433) in combination with Ferring’s intravesical non-replicating gene therapy ADSTILADRIN(nadofaragene firadenovec-vncg) for adult patients diagnosed with high-risk Bacillus Calmette-Guérin (“BCG”)-unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) with or without papillary tumors (±Ta/T1). Under the terms of the Agreement, Theralase® will remain the sponsor of the study, with both parties providing clinical overview of the new cohort through a joint development committee. The new cohort will be enrolled and treated in the United States and then subject to written agreement may expand into Canada or other countries. “The introduction of ADSTILADRIN, as the first intravesical gene therapy, … Read More

Newsfile | Dec 23, 2025 4:40 PM EST Toronto, Ontario–(Newsfile Corp. – December 23, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering (“Offering“) of units (“Units“). On closing, the Corporation issued an aggregate of 7,850,882 Units at a price of $CAN 0.17 per Unit for aggregate gross proceeds of approximately $CAN 1,334,650. Each Unit consists of one common share of the Company (“Common Share“) and one common share purchase warrant (“Warrant“). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $CAN 0.21 per share for a period of 5 years following the date of closing. The Company plans to use the proceeds of the financing to … Read More

Newsfile | Dec 12, 2025 5:00 PM EST Toronto, Ontario–(Newsfile Corp. – December 12, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company (“Units“) to raise up to $CAN 2,000,000 (“Offering“). In the Offering, each Unit is priced at $CAN 0.17 and consists of one common share of the Company (“Common Share“) and one Common Share purchase warrant (“Warrant“). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company (“Warrant Share“) for a period of 60 months following the Closing Date (as defined herein) of the Offering at an exercise price of $CAN 0.21 per Warrant Share. The Company plans to use the proceeds of the Offering to further the Phase II Non-Muscle … Read More

Newsfile | Nov 24, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation (“RCC“) as the sole agent and bookrunner on a commercially reasonable “best efforts” agency basis, for a brokered private placement offering (“Offering“) of units of the Company (“Units“) at a price of C$ 0.17 per Unit to raise a minimum of C$ 4,500,000 and up to a maximum of C$5,500,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company (“Common Share“) and one Common Share purchase warrant (“Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share (“Warrant Share“) at an … Read More

Nov 17, 2025 7:00 AM EST Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario–(Newsfile Corp. – November 17, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company’s ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) (“Study II“), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025. Participants are encouraged to submit questions in advance to mperraton@theralase.com to ensure sufficient time for discussion. Zoom Meeting Link: https://us02web.zoom.us/j/81044841120Webinar ID: 810 4484 1120 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) … Read More

Nov 10, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 10, 2025) – Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company’s unaudited condensed consolidated interim 3Q2025 financial statements (“Financial Statements“). Theralase® will be hosting a conference call on Wednesday, November 19th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending September 30th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com. Zoom Meeting Link:   https://us02web.zoom.us/j/81044841120Webinar ID: 810 4484 1120 Conference Call in:  1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom   An archived version will be available on the website following the conference call. Financial Summary:For the nine-month period … Read More

Nov 3, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 3, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to share a scientific poster which demonstrates the effectiveness of X-Ray-activated Rutherrin® for numerous cancers in preclinical models. Theralase® was unable to attend the presentation of the poster in person titled, “Rutherrin® Activated by Radiation Therapy Induces Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models.” The abstract has been published in the International Journal of Radiation Oncology – Biology – Physics at the following link: Rutherrin® Activated by Radiation Therapy and Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models – ScienceDirect The full poster is available at the following link: Research Publications | Theralase Technologies Inc. – … Read More

Sep 24, 2025 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – September 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral candidate, Ruvidar®, in the destruction of Herpes Simplex Virus Type 1 (“HSV-1“). The latest preclinical data was published in MDPI – Viruses titled, “Ruvidar®-An Effective Anti-Herpes Simplex Virus Agent” and is available for viewing at: Website: https://www.mdpi.com/1999-4915/17/9/1280PDF Version: https://www.mdpi.com/1999-4915/17/9/1280/pdf This peer-reviewed publication provides strong support that Ruvidar® is more effective in the treatment of HSV-1 than either Acyclovir® or Metformin®, even without light-activation. Acyclovir® and its derivatives are currently known as the gold standard treatment for HSV-1.1 According to this latest research, Acyclovir® and Metformin® had little, if any, effect on the virus, once infection … Read More